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Chapter 8
Clinical, cellular, and molecular aspects of arterial
calcification
Raul J. Guzman, MD, Nashville, Tenn
Arterial calcification is a complex and independently regulated process with risk factors similar to those for atherosclerotic
occlusive disease. It may develop either within the atherosclerotic intima or in the media. When calcification is found in
coronary or lower extremity arteries, it is an independent predictor of cardiovascular events and lower extremity
amputation. Recent evidence suggests a role for several endogenous stimulators and inhibitors in the pathogenesis of
arterial calcification. Inflammatory mediators and matrix-degrading enzymes are also thought to control the progression
of calcification in humans. Current research involves efforts to define the complex interactions between cellular and
molecular mediators of arterial calcification. (J Vasc Surg 2007;45:57A-63A.)Arterial calcification was previously viewed as an inevi-
table, passive, and degenerative process that occurred at the
end stages of atherosclerosis. Recent studies, however, have
demonstrated that calcification of arteries is a complex and
regulated process.1,2 It may occur in conjunction with
atherosclerosis or in an isolated form that is commonly
associated with diabetes and renal failure.3,4 Higher artery
calcium scores are associated with increased cardiovascular
events, and some aspects of arterial calcification are similar
to the biology of forming bone.5,6 Arterial calcification can
thus be viewed as a distinct inflammatory arteriopathy,
much like atherosclerosis and aneurysms, with its own
contribution to cardiovascular morbidity and mortality.7
Current research involves efforts to define the complex
interactions between cellular and molecular mediators of
arterial calcification and, in particular, the role of endoge-
nous calcification inhibitors. This review discusses the clin-
ical relevance, cellular events, and suspected molecular
pathways that control arterial calcification and highlight
some potential avenues for future research.
CLINICAL ASPECTS
Population studies. At least one third of Americans
aged 45 years have arterial calcification when assessed by
computed tomography (CT).8,9 Risk factors for the devel-
opment of early coronary artery calcification are similar
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hypertension, increased body mass index, and low high-
density lipoprotein cholesterol.10 In asymptomatic volun-
teers aged 50 years, coronary artery calcification is asso-
ciated with increasing age, triglycerides, cholesterol, and
increased intra-abdominal fat.11
The presence of diabetes significantly raises the risk of
coronary calcification, and end-stage renal disease is
thought to result in increased arterial calcium accumulation
due to abnormalities in calcium and phosphorus homeosta-
sis.12-14 Common risk factors between atherosclerosis and
calcification, and the high incidence of concurrent disease,
have complicated our ability to separate the contribution of
each to clinical events.
Recent data on lower extremity amputation, mortality,
and coronary events confirm a strong predictive role of
arterial calcium accumulation that persists even after cor-
rection for traditional risk factors. For example, when high
coronary artery calcification is identified by electron beam
or spiral CT, it predicts a fivefold to sevenfold increase in
the risk of hard coronary events and this risk persists despite
correction for age.15,16 Similar predictive value is associated
with calcification identified in the aortic arch.17 When
arterial calcification is specifically identified in the mid-
thigh femoral artery, it is associated with a nearly threefold
increase in the risk of amputation.18,19
Although themechanisms whereby arterial calcification
leads to increased vascular events are currently unknown,
recent data suggest that coronary events and end-organ
damage are relatedmore to increased arterial stiffness rather
than to the associated occlusive lesions.20,21 Further at-
tempts to characterize the effects of increased arterial stiff-
ness on end organs are needed, as are methods to distin-
guish the effects of calcification from those of
atherosclerotic lesions.
Histology. Vascular calcification has been divided
into four forms that involve (1) the atherosclerotic intima,
(2) the media of medium and large sized arteries, (3)
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phylaxis.22 The second form, known as medial artery calci-
fication or Mönckeberg sclerosis, is of primary importance
in the diabetic population and particularly in patients with
diabetic tibial artery disease. Medial artery calcification may
be found in conjunction with atherosclerotic lesions, or it
may occur independently.2 It occurs in patients with nor-
mal serum calcium and phosphorus levels, and this distin-
guishes it from vascular calciphylaxis, which is related to
high serum calcium and phosphate levels that result in
passive mineral deposition onto elastic fibers.22 Of these
forms, medial artery calcification has been most strongly
associated with cardiovascular events.18
The expression of bone-related genes in atherosclerotic
lesions was described more than a decade ago.23,24 Arteries
from patients with medial calcification have increased ex-
pression of osteoprotegrin, a member of the tumor necrosis
factor (TNF) ligand and receptor-signaling family. This is
associated with apoptosis that occurs next to areas of recent
calcification.25 In clinical specimens, medial artery calcifi-
cation occurred next tomedial smoothmuscle cells (SMCs)
and in the absence of macrophages or lipids. Compared
with control arteries, these vessels expressed less matrix Gla
protein (MGP) and osteonectin and more alkaline phos-
phatase, bone sialoprotein, bone Gla protein, and collagen
II, all indicators of osteogenesis or chondrogenesis.26
Cells residing in the media of human calcified arteries
lose their expression of SMC markers and begin to express
more osteogenic or chondrogenic markers, including the
osteochondrogenic transcription factors Cbfa1, Msx2, and
Sox9.27 These studies on human specimens show arterial
changes that resemble the biology of developing bone.
They have helped us form hypotheses on the basic mecha-
nisms that initiate and regulate arterial calcification.
Although our understanding of the specific pathologic
events that incite arterial calcification remains limited, the
factors that predispose to its development have recently
been defined, and attempts to place these findings in per-
spective have begun.2 It is thought that poor glucose
control leads to a low-grade inflammatory response in the
adventitia that is related to chronic metabolic, osmotic, and
oxidative stresses.28 These oxidative and hyperlipidemic
signals may then induce the secretion of inflammatory
mediators such as TNF-, interleukin (IL) 6, and adipo-
kines from macrophages in the arterial wall.29,30 Moreover,
patients with elevated levels of soluble IL-2 receptor, a
marker of T-cell activation, have increased rates of coronary
calcium progression compared with controls.31 The com-
plex interplay between risk factors, inflammatory media-
tors, and the development of occlusive vs calcific lesions will
need further evaluation and scrutiny.
CELLULAR ASPECTS
The media: smooth muscle cells and calcifying vas-
cular cells. The ability of medial SMCs to undergo phe-
notypic transformation was recognized 25 years ago by
Campbell et al.32 Phenotypic SMC changes that occur
during calcification have only recently been described,however.33 SMCs cultured from the aortic wall have mul-
tilineage potential with the ability to express chondrogenic,
leiomyogenic, and stromogenic markers, but not adipo-
genic markers.34
Studies by Demer et al35 have demonstrated that cer-
tain populations of medial SMCs, when grown in culture,
are capable of undergoing calcification. These cells, known
as calcifying vascular cells (CVCs), can differentiate into
osteoblast-like cells while losing their ability to express
smooth muscle-specific markers.36 This suggests that the
changes in cellular phenotype that occur during calcifica-
tion may occur through the transformation of a subpopu-
lation of medial SMCs intomore osteogenic cells, and these
changes may occur in the setting of diminished inhibitors
or increased stimulators of calcification. The in vivo origin
of these osteoblastic cells, however, has not been deter-
mined.
The adventitia: pericytes, fibroblasts, and mesen-
chymal stem cells. A program of osteogenic expression
has been described in the arterial wall of LDLR–/– mice fed
a high fat, diabetogenic diet.28 This work, done by Towler
et al,37 demonstrated up-regulation of osteoblastic tran-
scription factors Msx2 and Msx1 in perivascular adventitial
cells. Msx2, which is thought to act in response to stimu-
lation by bone morphogenetic proteins (BMPs), stimulates
osteogenesis in adventitial myofibroblasts and in cells from
a mesenchymal stem cell line while inhibiting adipogenic
differentiation. In addition, mice carrying the CMV-Msx2
transgene have increased expression of Msx2 only in the
adventitia, whereas alkaline phosphatase expression is in-
creased only in the media.38
They further evaluated conditioned media from Msx2-
stimulated mesenchymal cells and found that it induced
expression of Wnt signaling molecules, TCF/Lef transcrip-
tion, and nuclear -catenin localization with concomitant
alkaline phosphatase induction.38 This strongly suggests
that a subset of adventitial cells expressing a bone morpho-
genic protein 2 (BMP-2)-Msx2 signaling program can
influence the phenotype of medial cells and may be respon-
sible for inducing calcification.
In cell culture experiments on microvascular pericytes,
dexamethasone, a steroid with recognized stimulatory ef-
fects on vascular calcification, down-regulates molecules
thought to act as calcification inhibitors including MGP,
osteopontin, and vascular calcification-associated factor
(VCAF).39 Advanced glycation end products increase cal-
cification and osteoblastic differentiation of microvascular
pericytes.40 Therefore, cells expressing osteochondrogenic
markers during calcification may represent medial cells
responding to adventitial signals or precursor cells that are
recruited into the media from surrounding tissues or from
the blood stream.
Angiogenesis and the role of endothelial cells. A
potential association between angiogenesis and the pro-
gression of arterial calcification has recently been pro-
posed.41 According to this hypothesis, osteogenic signals
or osteogenic precursor cells may be conveyed into the
arterial wall by collateral vessels that develop in response to
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relationship between angiogenesis and the progression of
atherosclerotic plaques.6 Inhibitors of angiogenesis prevent
the progression of atherosclerotic plaques,42 whereas stim-
ulators of angiogenesis enhance plaque progression.43
Inflammatory collaterals have been shown to originate
from the adventitia.44 Once established, it is proposed that
these collateral vessels may allow for the migration of
multipotent adventitial myofibroblasts or pericytes into the
atherosclerotic intima or media where they can differentiate
into osteoblast-like cells through the effects of bone-
signaling proteins such as the BMPs and osteoprotegrin.
Alternatively, the collaterals can be used to convey signals
secreted by adventitial cells to the media, where they can
affect the phenotype of calcifying vascular cells.
Of note is that arteries from rats that underwent re-
moval of the adventitia had reduced amounts of medial
calcification on a calcification-inducing diet.45 In addition,
endothelial cells exposed to atherogenic stimuli in culture
demonstrated increased expression of MGP and BMP2.46
Endothelial cells grown in culture with CVCs can either
inhibit or stimulate calcification, depending on the specific
culture conditions, and this is thought to be related to their
expression of BMP2.47 However, direct in vivo confirma-
tion of a relationship between angiogenesis and arterial
calcification has not been demonstrated.
MOLECULAR ASPECTS
Smooth muscle cell calcification in vitro. Numerous
factors have been shown to affect the ability of media-
derived cells to undergo calcification in vitro (Table).48-77
Shortly after their identification of CVCs from bovine
aorta, Demer et al51 demonstrated that in vitro calcification
was enhanced by the addition of two atherosclerosis-








Acetylated LDL53,54 *Matrix Gla Protein70
Homocysteine37 Osteopontin71,72
Glucose 55 *Osteoprotegrin73
Endothelin-156 *NPP-1 via Pip73





TGF,Transforming growth factor; cAMP, cyclic adenosinemonophosphate;
BMP, bone morphogenic protein; MAP, mitogen-activated protein kinase;
LDL, low-density lipoprotein; NPP, nucleotide pyrophosphatase phospho-
diesterase; PPi, inorganic pyrophosphate.
Factors shown to affect calcification in vivo are in bold.
*Denotes data from mice with spontaneous or targeted gene alteration.promoting proteins—transforming growth factor 1(TGF-1) and 25-hydroxycholesterol—and they sug-
gested a link between calcification and atherosclerosis.
Other factors thought to be involved in atherosclerosis
progression were also found to affect the ability of CVCs to
calcify. For example, CVCs are responsive to the effects of
estrogen35 and to the effects of the intracellular-signaling
molecules cyclic adenosine monophosphate36 and mitogen-
activated protein kinase (MAPK).52 N-3 fatty acids inhibit
calcification of CVCs though p38-MAPK and peroxisome
proliferator-activated receptor- pathways,63 and leptin,
the circulating protein product of the ob gene, promotes
osteoblastic differentiation and calcification of CVCs by
increasing alkaline phosphatase activity.58 In addition,
macrophages are thought to exert their procalcification
effects on CVCs through secretion of TNF-.29
Cultured SMCs are also capable of undergoing calcifi-
cation and expressing osteogenic phenotypes when they are
exposed to high levels of inorganic phosphates.78,79 This
process is stimulated by high glucose, which increases the
expression of Cbfa1 and BMP-2,55 and it is inhibited by
osteopontin and inorganic pyrophosphate.48-50 Acetylated
low-density lipoprotein and homocysteine stimulate vascu-
lar SMC calcification,53,54 whereas statins prevent calcifica-
tion through effects on the Gas6-Axl survival pathway.62
Endothelin-1 blockade prevents calcification of cultured rat
SMCs and it also has effects in vivo.56 Matrix proteins,
including elastin precursors, elastin degradation products,
and decorin, a proteoglycan found in human calcified
plaques, are also known to enhance SMC calcification in
vitro.65,65,80
Of interest is that BMP-7may counter the calcification-
inducing effects of BMP-2 by promoting the SMC pheno-
type.66 SMC calcification and phenotypic transformation
into chondrocyte-like cells is also affected by altering levels
of the sodium-dependent phosphate cotransporter Pit-1,
suggesting that phosphate uptake by Pit-1 is essential for
phosphate-induced SMC calcification and phenotype
changes.67
Arterial calcification in rats: calcium, phosphorous,
and bone resorption. Much of the early experimental
data on medial calcification came from studies in rats over-
dosed with vitamin D.81 Arterial calcification in this model
is accompanied by calcification in the lungs and other
tissues. It is most similar to human calciphylaxis.2,82 High
serum levels of calcium and phosphate are similar to levels
seen in dialysis patients and those with parathyroid axis
dysfunction.22 Vitamin D3 also increases vascular SMC
calcification in vitro, and this effect is partially mediated by
inhibition of parathyroid hormone–related peptide expres-
sion.83
The earliest finding in calcification induced by vitamin
D3 is that of matrix vesicles developing along elastin fibers,
and this is similar to what has been seen in human speci-
mens.84,85 This is followed by deposition of calcium hy-
droxyapatite crystals along the elastic lamellae and degen-
eration of medial elastin.84,86 Once the calcification process
is initiated, it is thought to spread along the elastin fibers,
ultimately leading to destruction of the elastin fibers them-
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smooth muscle cells.59 Calcification in this model is gener-
ally thought to occur in the absence of an inflammatory cell
infiltrate and is linked to bone resorption.87
Characterized by decreased levels of circulating fetuin-
A, it can be delayed by inhibitors of bone resorption,
including the cytokine osteoprotegrin and the amino
bisphosphonates.67-69 Calcification can also be reduced by
V-H-adenosine triphosphatase inhibitor SB 24278488
and sevelamer, a phosphate binder that does not contain
calcium.89 These studies by Price et al suggest that arterial
calcification may be related to serum factors emanating
from resorbing bone.
In humans, there is a known association between os-
teoporosis and arterial calcification.90,91 Although calcifi-
cation in these models is not thought to involve an inflam-
matory intermediate, it is likely that certain mechanisms
overlap with those of other forms of calcification. For
example, localized changes in extracellular calcium or phos-
phorus concentrations may be involved in the initial stages
of medial and intimal calcification or in their progression.33
In addition, we have recently shown that systemic admin-
istration of the antibiotic doxycycline, which has properties
that inhibit matrix metalloproteinase activity, can reduce
arterial calcification in rats treated with vitamin D.60
Another model of arterial calcification in rats involves
the use of warfarin and vitaminK that are thought towork by
reducing levels of MGP. Arterial calcification in warfarin-
treated rats is accelerated by growth and vitamin D.92 It can
be reversed by treatment with an endothelin receptor an-
tagonist and this appears to be dependent on activation of
membrane bound carbonic anhydrase IV.93 Finally, arterial
calcification can also be induced in rats by feeding with an
adenine-containing diet that causes uremia.94 It has re-
cently been demonstrated that calcification in this model is
increased by diets low in protein and reduced by the bone
resorption inhibitor ibandronate.95
Studies using rats injected with vitamin D have yielded
significant information during the last 40 years; however,
calcification in this model appears to be most similar to
human vascular calciphylaxis because rats do not develop
intimal lesions or similar inflammatory responses. There-
fore, recent work in genetically altered mouse strains that
spontaneously develop arterial calcification gives new op-
portunities to study this complex process.
Arterial calcification in mice: role of endogenous
inhibitors. Evidence for endogenous calcification inhibi-
tors comes from targeted or spontaneous gene alterations
in mice. Mice deficient in the vitamin K–dependent protein
MGP, a mineral-binding extracellular matrix protein, have
chondrocytes within the arterial wall. They develop arterial
calcification shortly after birth, and this results in death
from arterial rupture in 3 months.70 The mechanisms by
which MGP deficiency leads to increased calcification re-
main unknown but may be related to interactions between
MGP and BMP2.96,97 Another potential interaction occurs
between MGP and osteopontin, which also accumulates
adjacent to calcifying areas. Mice deficient in both MGPand osteopontin had twice as much arterial calcification and
died significantly earlier than control MGP-deficient
mice.70,98 Thyroid hormone is also thought to increase
vascular SMC calcification through upregulation of
MGP.99
Mice with a genetic deficiency leading to decreased
inorganic pyrophosphate production develop spontaneous
calcification through an endochondral process.61 The de-
crease in inorganic pyrophosphate production is related to
a mutation that inhibits the catalytic activity of nucleotide
pyrophosphatase phosphodiesterase 1 (NPP-1). This mu-
tation was initially identified as a cause of most of the cases
of human idiopathic infantile arterial calcification.100 Cul-
tured aortic vascular SMCs isolated from mice deficient in
NPP-1 had increased expression of the chondrogenic
marker type II collagen and increased expression in aortic
specimens of the mature chondrocyte marker type IX/XI
collagen. In an organ culture model of aortic calcification,
high phosphate and calcium levels are unable to induce
calcification because of inhibition by pyrophosphate.50
Another genetic alteration resulting in spontaneous
arterial calcification is a mutation in the gene encoding for
osteoprotegrin, a member of the TNF superfamily of pro-
teins, which is also expressed in human atherosclerotic
lesions. It is a secreted osteoclast inhibitor, and mice defi-
cient in osteoprotegrin demonstrate decreased bone den-
sity and increased aortic and renal artery medial calcifica-
tion.73 This appears similar to the known association
between osteoporosis and arterial calcification in hu-
mans.91 Apolipoprotein E–/– mice with inactivated osteo-
protegrin demonstrate accelerated atherosclerotic lesion
progression and calcification with reduced cellularity of
lesions.101 Osteoprotegrin also inhibits calcification in rats
given warfarin or high doses of vitamin D.82
More recently, the serum protein 2-Heremans-
Schmid glycoprotein (Ahsg, also known as fetuin-A) has
been identified as an important inhibitor of ectopic calcifi-
cation. Mice deficient in Ahsg are phenotypically normal
but develop calcification when placed on a diet containing
increased calcium, phosphate, and vitamin D.74 Arterial
calcification occurred in the absence of elevated serum
calcium or phosphorus levels and resulted in increased
blood pressure and renal failure. In vitro experiments
showed that lack of Ahsg was associated with a lack of
inhibitory activity of serum proteins on bone calcium phos-
phate precipitation, suggesting that the effects of Ahsg
were systemic rather than specifically on the arterial wall.
This study supports the notion that many factors in addi-
tion to serum calcium and phosphorus levels are important
in the development of arterial calcification, even in patients
with renal failure.
Three additional mouse strains are known to develop
calcification, but mechanistic studies have not been reported.
Mice without the gene encoding for the Smad6 homologue
Madh6, an intracellular inhibitor of TGF- signaling, develop
arterial calcification and cartilaginous metaplasia possibly
through release of the BMP-2 signaling cascade.75 Mutations
in the mouse klotho gene cause a phenotype that resembles
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related to increased serum phosphate levels.76 Mice with a
defect in the gene encoding for carbonic anhydrase 2 show
calcification in small arteries.77 Attempts to define the mech-
anisms by which these factors, and others, lead to arterial
calcification are ongoing.
Matrix degradation in arterial calcification. Matrix
metalloproteinases (MMPs) are known to play diverse roles
in arterial pathologic processes.102 They have been demon-
strated to exert multiple effects during atherosclerosis, re-
stenosis, and aneurysmal degeneration.102 A role of MMPs
in arterial calcification was previously demonstrated by
Basalyga et al,59 who focused on the importance of elastin
degradation. Their work suggests that elastolyticMMPs are
secreted by inflammatory cells in the adventitia or media,
with consequent degradation of medial elastin. This leads
to the release of elastin degradation products that, in turn,
act as chemokines to recruit other inflammatory cells. A
cycle of MMP-mediated elastin degradation, recruitment
of inflammatory cells, and more MMP secretion ensues.
Inhibiting MMP activity would serve to stop this cycle
and prevent the influx of new inflammatory cells. We have
recently demonstrated efficacy of an MMP inhibitor in
limiting calcium chloride–induced aortic calcification. We
observed reduced aortic calcification in rats that were
treated with GM6001, a nonselective, synthetic MMP in-
hibitor.92
MMPs are also known to have nonmatrix effects during
osteogenesis,103 and they are involved in several aspects of
mesenchymal stem cell renewal and differentiation.104 Re-
cent work has demonstrated that osteopontin promotes
pro-MMP9 activation in aortic mesenchymal cells.105 This
suggests that the role of matrix-degrading enzymes during
arterial calcification may go beyond that of degrading me-
dial elastin. Current work in our laboratory is focused on
addressing these issues.
CONCLUSIONS
Artery calcification is a complex and regulated process
that may occur in conjunction with atherosclerosis or in a
more isolated form. It is now known to be an independent
predictor of cardiovascular events, including lower extrem-
ity amputation. Multiple stimulators and inhibitors control
the progression of vascular calcification, and it is likely to
involve inflammatory mediators emanating from cells lo-
cated in the arterial wall or the surrounding adventitia.
Matrix effects also control the progression of calcification.
Future work will involve unraveling of the molecular events
leading to calcification and the development of novel mo-
lecular-based therapies to prevent its progression.
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